MTVAHealthcare · BiotechnologyMTVA Stock Forecast: MetaVia, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering MetaVia, Inc. hold a median 12-month price target of $20 — +1251.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
MTVA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores MetaVia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own MetaVia, Inc. — and when they’d sell — is the membership.
MTVA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MTVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1251.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $12 |
| 19 May 2025 | Maxim Group | Maintains | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MTVA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
MetaVia, Inc. (MTVA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- 0.8×
- EV / EBITDA
- 0.4×
Cheaper than 77% of US stocks
Cheaper than 76% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −195.1%
- Return on assets
- −65.3%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MTVA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MTVA appears on the weeks it earns a place.
Frequently asked questions about MTVA stock
What is the MTVA stock price forecast for 2026-2027?
The 2 Wall Street analysts covering MetaVia, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MTVA stock a buy right now?
Of the 2 analysts covering MetaVia, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MetaVia, Inc. 18 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MTVA?
As at 1 Aug 2026, MetaVia, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
Will MTVA stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1251.4% from the last close, and Ticker Nerd's factor model ranks MetaVia, Inc. 18 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MTVA stock forecast for 2030?
No analyst covering MetaVia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.
How has MTVA stock performed over the past year?
MetaVia, Inc. returned -77.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MetaVia, Inc. do?
MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions.
About MetaVia, Inc.
MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing multi-modal, disease-modifying therapies for serious metabolic and neurological conditions. The company concentrates on cardiometabolic diseases, including obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), as well as select central nervous system disorders. Its current pipeline includes DA-1726, being developed for obesity, and vanoglipel (DA-1241), a GPR119 agonist targeting MASH with potential relevance to Type 2 Diabetes Mellitus through modulation of gut hormones such as GLP-1, GIP, and peptide YY. MetaVia also develops ANA001, a proprietary oral niclosamide formulation, Gemcabene for acute indications including infectious and inflammatory settings, NB-01 for painful diabetic neuropathy, and NB-02 aimed at symptoms of cognitive impairment in neurodegenerative diseases. Operating within the biotechnology and health technology sectors, MetaVia plays a specialized role in addressing complex, high-burden diseases where there is significant medical need for new therapeutic options.
CEO Mr. Hyung Heon Kim · 8 employees · United States · https://www.metaviatx.com